Results 1 to 10 of about 21,799 (237)
Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices [PDF]
ACR Open Rheumatology, 2020 Objective It is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Nick Bansback +8 more
doaj +2 more sources
Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel [PDF]
Frontiers in Pharmacology, 2017 Introduction: Introducing biosimilar infliximab for the treatment in rheumatology (rheumatoid arthritis and ankylosing spondylitis) and inflammatory bowel disease (Crohn's disease and ulcerative colitis) may reduce treatment costs associated with ...
Tim A. Kanters +5 more
doaj +7 more sources
Journal of the European Academy of Dermatology and Venereology, 2018 Linked article: This is a commentary on P. Yamauchi et al., pp. 1066–1074 in this issue.
Sandeep, Parsad, Chadi, Nabhan
+13 more sources
Lupus, 2020 Biological therapies have widened the therapeutic armamentarium for immune-mediated inflammatory diseases, providing in many cases a broad range of treatment options with different mechanisms of action. The widespread use of biological agents in systemic lupus erythematosus is currently limited to belimumab and rituximab, although results of promising
Christopher J Edwards +1 more
+6 more sources
Unambiguous identification of α-Gal epitopes in intact monoclonal antibodies by NMR spectroscopy
mAbs, 2022 The α-Gal epitope consisting of the terminal trisaccharide Galα1,3Galβ1,4GlcNAc exposed on cell or protein surfaces can cause severe immune reactions, such as hypersensitivity reactions, in humans.
Arthur Hinterholzer +6 more
doaj +1 more source
An international comparative analysis and roadmap to sustainable biosimilar markets
Frontiers in Pharmacology, 2023 Background: Although biosimilar uptake has increased (at a variable pace) in many countries, there have been recent concerns about the long-term sustainability of biosimilar markets.
Khalid A. Alnaqbi +22 more
doaj +1 more source
Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain
Pharmaceuticals, 2021 Incentives contribute to the proper functioning of the broader contracts that regulate the relationships between health systems and professionals.
Félix Lobo, Isabel Río-Álvarez
doaj +1 more source
PLoS ONE, 2022 Healthcare systems have reached a critical point regarding the question of whether biosimilar substitution should become common practice. To move the discussion forward, the study objective was to investigate the views of experts from medicines agencies ...
Louise C. Druedahl +6 more
doaj +2 more sources
Knowledge and Perception of Iraqi Pharmacists Towards Biosimilar Medicines
Iraqi Journal of Pharmaceutical Sciences, 2021 Biosimilars are non-innovative copy versions of biologic medicines which are proven to be clinically equivalent to, as effective and as safe as their reference biologics.
Ashwaq J. Mohammed, Dheyaa J. Kadhim
doaj +1 more source
Scientific Reports, 2022 TNF-alpha inhibitors have revolutionized the therapeutic care in chronic inflammatory diseases. Several biosimilar products were commercialized at their patent expiry, substantially decreasing the cost of treatment.
Hugo Jourdain +3 more
doaj +1 more source